After a defeat in a patent dispute in the morning, the share price of the biotech company Morphosys falls on Monday. The stock was listed with 96,80 Euro up to 8.2 percent lower, before she was able to relax a little. A district court in the us state of Delaware has declared three patents of the German company in a patent dispute between Morphosys and the biotech company Janssen Biotech and Genmab invalid. The court granted a request by Janssen and Genmab, to declare the three patents are invalid.
Morphosys may appeal against the judgment nor appealed to the Federal court, has met but as yet no decision. The company based in Planegg, near Munich, had collected in front of the district court of Delaware patent infringement lawsuit against Janssen and Genmab and compensation claimed. It went to an antibody by Janssen and Genmab, which is directed against a specific Protein. The patents of Morphosys include antibodies with certain properties, which bind to such a Protein.
A for Morphosys is a favourable decision would have brought to the company according to the analyst Gunnar Romer from Deutsche Bank, significant sales of interests in the anti-cancer agent Darzalex of Janssen. Romer himself had taken into account this aspect, however, in its assessment model only with 6 euros per share, and is also of less importance in the evaluation of other experts. In this respect potential positive effects have been priced in anyway, just a little. Accordingly, there is a significant Price setback offering a good buying opportunity, Romer. Nevertheless, Romer lowered his price target from 130 to 125 Euro.
MORPHOSYS — — (–) Xetra tradegate London SE Int. Level 1StuttgartFrankfurtLang & black Switzerland OTCSchweizWien 1T 1W 3M 1J 3J 5J For detail view